E

Exelixis
D

EXEL

39.600
USD
0.70
(1.80%)
مغلق
حجم التداول
82,111
الربح لكل سهم
2
العائد الربحي
-
P/E
23
حجم السوق
10,913,124,618
أصول ذات صلة
ABBV
ABBV
5.160
(2.67%)
198.440 USD
AZN
AZN
1.940
(2.75%)
72.440 USD
BMY
BMY
1.000
(2.02%)
50.560 USD
C
CRVS
0.12000
(3.43%)
3.62000 USD
INCY
INCY
0.500
(0.81%)
62.500 USD
MRK
MRK
-0.090
(-0.11%)
83.160 USD
N
NKTR
-0.02630
(-3.38%)
0.75210 USD
PFE
PFE
0.065
(0.27%)
24.185 USD
المزيد
الأخبار المقالات

العنوان: Exelixis

القطاع: Healthcare
الصناعة: Biotechnology
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.